Stay Ahead with the Latest in Finance

Berenberg has recently disclosed its trading activity in Dalata Hotel Group shares, prompting analysis of market implications for the hospitality sector.

RBC Capital has raised the price target for Apellis Pharmaceuticals stock to $22, showcasing an optimistic outlook amid changing market dynamics.

RBC adjusts CorMedix price target to $21 based on updated TDAPA analysis, influencing investor strategies amidst regulatory changes.

Thyssenkrupp’s recent spinoff has significantly impacted TKMS shares, leading to a surge while the parent company faces an 18% decline.

The Bank of Korea is poised to maintain its interest rates amid ongoing economic challenges with foreign exchange stability and housing market concerns.

Canaccord Genuity’s Buy rating for GeneDx highlights its strong market position and growth potential in the genomic testing industry.

BofA Securities has raised Apellis Pharmaceuticals stock price target to $29, reflecting a positive outlook for the biotech company.

BofA has increased the price target for PTC Therapeutics to $87, reflecting confidence in its growth trajectory.

Canaccord Genuity has reaffirmed a ‘Buy’ rating for Tempus AI stock, setting a target price of $110 and highlighting market confidence.